Cargando…
Bioactivities of EF24, a Novel Curcumin Analog: A Review
Curcumin is an attractive agent due to its multiple bioactivities. However, the low oral bioavailability and efficacy profile hinders its clinical application. To improve the bioavailability, many analogs of curcumin have been developed, among which EF24 is an excellent representative. EF24 has enha...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297553/ https://www.ncbi.nlm.nih.gov/pubmed/30619754 http://dx.doi.org/10.3389/fonc.2018.00614 |
_version_ | 1783381185480622080 |
---|---|
author | He, Yonghan Li, Wen Hu, Guangrong Sun, Hui Kong, Qingpeng |
author_facet | He, Yonghan Li, Wen Hu, Guangrong Sun, Hui Kong, Qingpeng |
author_sort | He, Yonghan |
collection | PubMed |
description | Curcumin is an attractive agent due to its multiple bioactivities. However, the low oral bioavailability and efficacy profile hinders its clinical application. To improve the bioavailability, many analogs of curcumin have been developed, among which EF24 is an excellent representative. EF24 has enhanced bioavailability over curcumin and shows more potent bioactivity, including anti-cancer, anti-inflammatory, and anti-bacterial. EF24 inhibits tumor growth by inducing cell cycle arrest and apoptosis, mainly through its inhibitory effect on the nuclear factor kappa B (NF-κB) pathway and by regulating key genes through microRNA (miRNA) or the proteosomal pathway. Based on the current structure, more potent EF24 analogs have been designed and synthesized. However, some roles of EF24 remain unclear, such as whether it induces or inhibits reactive oxygen species (ROS) production and whether it stimulates or inhibits the mitogen activated kinase-like protein (MAPK) pathway. This review summarizes the known biological and pharmacological activities and mechanisms of action of EF24. |
format | Online Article Text |
id | pubmed-6297553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-62975532019-01-07 Bioactivities of EF24, a Novel Curcumin Analog: A Review He, Yonghan Li, Wen Hu, Guangrong Sun, Hui Kong, Qingpeng Front Oncol Oncology Curcumin is an attractive agent due to its multiple bioactivities. However, the low oral bioavailability and efficacy profile hinders its clinical application. To improve the bioavailability, many analogs of curcumin have been developed, among which EF24 is an excellent representative. EF24 has enhanced bioavailability over curcumin and shows more potent bioactivity, including anti-cancer, anti-inflammatory, and anti-bacterial. EF24 inhibits tumor growth by inducing cell cycle arrest and apoptosis, mainly through its inhibitory effect on the nuclear factor kappa B (NF-κB) pathway and by regulating key genes through microRNA (miRNA) or the proteosomal pathway. Based on the current structure, more potent EF24 analogs have been designed and synthesized. However, some roles of EF24 remain unclear, such as whether it induces or inhibits reactive oxygen species (ROS) production and whether it stimulates or inhibits the mitogen activated kinase-like protein (MAPK) pathway. This review summarizes the known biological and pharmacological activities and mechanisms of action of EF24. Frontiers Media S.A. 2018-12-11 /pmc/articles/PMC6297553/ /pubmed/30619754 http://dx.doi.org/10.3389/fonc.2018.00614 Text en Copyright © 2018 He, Li, Hu, Sun and Kong. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology He, Yonghan Li, Wen Hu, Guangrong Sun, Hui Kong, Qingpeng Bioactivities of EF24, a Novel Curcumin Analog: A Review |
title | Bioactivities of EF24, a Novel Curcumin Analog: A Review |
title_full | Bioactivities of EF24, a Novel Curcumin Analog: A Review |
title_fullStr | Bioactivities of EF24, a Novel Curcumin Analog: A Review |
title_full_unstemmed | Bioactivities of EF24, a Novel Curcumin Analog: A Review |
title_short | Bioactivities of EF24, a Novel Curcumin Analog: A Review |
title_sort | bioactivities of ef24, a novel curcumin analog: a review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297553/ https://www.ncbi.nlm.nih.gov/pubmed/30619754 http://dx.doi.org/10.3389/fonc.2018.00614 |
work_keys_str_mv | AT heyonghan bioactivitiesofef24anovelcurcuminanalogareview AT liwen bioactivitiesofef24anovelcurcuminanalogareview AT huguangrong bioactivitiesofef24anovelcurcuminanalogareview AT sunhui bioactivitiesofef24anovelcurcuminanalogareview AT kongqingpeng bioactivitiesofef24anovelcurcuminanalogareview |